Clinical trial
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic…
NCT02696031 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT02696031 |
|---|---|
| Title | Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis |
| Official title | A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs |
| Acronym | PREVENT |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Non-radiographic Spondyloarthritis |
| Intervention type | Drug |
| Interventions | Secukinumab, Placebo |
| Enrollment | 555 |
| Start date | Apr 29, 2016 |
| Primary completion | Jul 1, 2019 |
| Completion | Mar 11, 2021 |
| First posted | Mar 2, 2016 |
| Last update posted | Apr 29, 2022 |
| Countries | Australia, Austria, Belgium, Bulgaria, Czechia, France, Germany, Hungary, Israel, Italy, Japan, Mexico and 12 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: